2020 News

07.28.2020 Press Release

Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired Blepharoptosis

07.22.2020 Press Release

Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program

07.07.2020 Press Release

Santen Announces U.S. FDA Acceptance of Premarket Approval (PMA) Application for DE-128 (MicroShunt) for Review

07.07.2020 Press Release

Santen Introduces its New Corporate Brand Name Notation and Corporate Slogan Aiming to Grow on a Globally, Going beyond the Pharmaceutical Industry

07.07.2020 Press Release

Announcement of New Vision Aiming to Resolve Social Issues Related to the Eye Health of People around the World

06.30.2020 Press Release

Santen and Singapore's Health-tech Start-up, Plano Form a Strategic Alliance to Tackle the Global Burden of Myopia

06.24.2020 Press Release

Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program

06.23.2020 Information

Santen's Proposed New Working Styles under the New Normal

06.18.2020 Press Release

Santen and Orbis International Join Forces to Expand Access to Training for Eye Care Professionals through Telemedicine Platform

06.17.2020 Information

Announcement of New Long-Term Vision

06.12.2020 Press Release

Providing Eye Care Information to Resolve Problems Caused by Excessive Screen Time

06.05.2020 Press Release

Bayer Yakuhin and Santen launch 'EYLEA Intravitreal Injection KIT 40mg/mL', pre-filled syringe of intravitreal VEGF Inhibitor EYLEA

05.19.2020 Information

Santen's Measures to Combat Novel Coronavirus Infections (COVID-19) (No. 3)

05.12.2020 Press Release

Notice of Board of Director and Corporate Auditor Nominations

05.08.2020 Press Release

Santen Reports Fiscal 2019 Consolidated Performance

05.08.2020 Press Release

Santen and jCyte Conclude an Exclusive Licensing Contract in Japan, Asia and Europe for the jCell Therapy Program for Retinitis Pigmentosa

04.28.2020 Press Release

Santen, Together with Nonprofit Organization, Japan Blind Football Association, to Support People with Visual Impairments Facing the COVID-19 Pandemic

04.27.2020 Press Release

Santen Introduces Eco-Friendly Biomass Plastic Eyedrop Bottles

04.01.2020 Information

Santen Pharmaceutical measures to combat the disease caused by the novel coronavirus (COVID-19)

03.25.2020 Press Release

Intravitreal VEGF Inhibitor EYLEA approved as a Treatment of Neovascular Glaucoma (NVG), its fifth indication

03.24.2020 Information

Santen's Measures to Combat Novel Coronavirus Infections (COVID-19) (No. 2)

03.13.2020 Press Release

Notice of Corporate Officer Appointments

03.10.2020 Press Release

Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration

03.05.2020 Press Release

Santen to Conduct Activities to Raise Awareness on Importance of Early Detection and Treatment of Glaucoma during World Glaucoma Week (March 8-14, 2020)

02.28.2020 Information

Santen's Measures to Combat Novel Coronavirus Infections (COVID-19) (No. 1)

02.27.2020 Information

Beware of Suspicious E-mails and Messages on Social Media Claiming to be from Santen Pharmaceutical Co., Ltd.

02.18.2020 Press Release

Notice of personnel change

02.04.2020 Press Release

Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Devices

02.04.2020 Press Release

Santen Reports the 3rd Quarter Fiscal 2019 Consolidated Performance

01.23.2020 Press Release

Santen Pharmaceutical Selected as Title Sponsor of IBSA Blind Football World Grand Prix 2020!

01.10.2020 Press Release

Santen Pharmaceutical Signs Partnership Agreement with ITU Supporting ITU and WHO initiative 'Be He@lthy, Be Mobile' in Ophthalmology

01.06.2020 Press Release

Santen Announces the Construction of China Second Plant